- Company
- 1st reimb. discussion to start on 2 tumor-agnostic therapies
- by Eo, Yun-Ho May 25, 2021 06:04am
- Two types of tumor-agnostic therapies seek reimbursement listing in Korea. Industry sources say Roche Korea’s Neurotrophic tyrosine receptor kinase(NTRK) Rozlytrek (entrectinib) and Bayer Korea’s ‘Vitrakvi (larotrectinib)’ will be up for deliberation by the National Health Insurance Service's (NHIS) Cancer Drug Review Committee meeti
- Company
- Keytruda leads domestic market sales … Perjeta·Prolia also
- by Chon, Seung-Hyun May 25, 2021 06:03am
- The cancer immunotherapy ‘Keytruda’ firmly held its lead in the domestic pharmaceutical market. This is the 5th consecutive quarter from the first quarter of last year that the drug has recorded top sales among all pharmaceuticals in Korea. Also, the new biopharmaceuticals introduced by multinational pharmaceutical companies like ‘Perjeta,’
- Company
- Samsung Biologics, commissioned to produce Moderna vaccine
- by Kim, Jin-Gu May 25, 2021 06:03am
- Samsung BioLogics signed a contract with Moderna on the 22nd (local time) to commission the production of COVID-19 vaccines. After producing undiluted corona vaccine abroad, Samsung BioLogics will charge and pack it in Korea. Samsung BioLogics CEO John Lim and CEO St&233;phane Bancel Moderna attended the "Korea-U.S. Vaccine Company Coope
- Company
- Organon’s spinoff from MDS to be completed in June
- by Eo, Yun-Ho May 24, 2021 05:51am
- Organon’s spinoff from MSD will soon be complete. Industry sources expect the administrative spin-off at the global headquarters of MSD and Organon to be completed within the next month (June). Following the spinoff, Organon & Co. will launch as a completely independent corporation in Korea as well. Organon’s Korean subsidiary has al
- Company
- Tagrisso's 1st-line reimb. necessary based on its OS benefit
- by May 24, 2021 05:51am
- With ‘Tagrisso (osimertinib)’ winning recognition as the first-line standard treatment for epidermal growth factor receptor (EGFR)-mutated advanced and metastatic non-small cell lung cancer, the demand for its reimbursement as first-line in Korea has also been increasing. At the Lung Cancer 1 session of the 19th Annual Symposium & Gener
- Company
- 8th meeting for Keytruda’s 3+ yrs pending reimb. to be held
- by Eo, Yun-Ho May 21, 2021 05:27am
- The cancer immunotherapy drug Keytruda will be up for its 8th deliberation by the Cancer Drug Review Committee. According to industry sources, MSD Korea’s application to expand the reimbursement of ‘Keytruda (pembrolizumab)’ to cover first-line treatment of non-small cell lung cancer (NSCLC) is expected to be put on the agenda for del
- Company
- ASCO 2021 preview: News drugs from Yuhan, Genexin, and Hanmi
- by An, Kyung-Jin May 21, 2021 05:27am
- The organizers of the 2021 ASCO Annual Meeting (ASCO 2021) released the accepted abstracts on the 19th (local time), two weeks ahead of the virtual event that will be held next month, from June 4-8. The ASCO meeting is considered one of the most important events for biopharmaceutical companies around the world in introducing the latest cl
- Company
- Tylenol is in short supply for a long time
- by Kim, Jin-Gu May 21, 2021 05:26am
- Along with the issue of side effects of COVID-19 vaccines in pharmacies, the shortage of Tylenol is intensifying. Domestic companies with generic products are expecting reflective profits. Several companies are said to have started marketing related to Tylenol shortages so that they can lead to increased sales of other generics of acetaminophen.
- Company
- Zopista for insomnia to be prescribed at general hospitals
- by Eo, Yun-Ho May 20, 2021 05:56am
- The insomnia treatment ‘Zopista,’ which can be prescribed long-term, is now cleared for prescription at general hospitals. According to industry officials, Huons’ Zopista(eszopiclone) passed the Drug Committees (DCs) of the Big-5s - Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, Samsu
- Company
- Piqray has been released in Korea
- by May 20, 2021 05:56am
- The first new drug targeting the PIK3 gene in breast cancer has been released in Korea. The MFDS approved Piqray (Alpelisib/50·150·200 mg' by Novartis on the 13th. Piqray is HR- (+)/HER2 (-) and may be combined with the endocrine treatment Faslodex (Fulvestrant) in postmenopausal women and men with progressive or metastatic breast can
